Securing Growth Capital Through a Capital and Business Alliance with Noritsu Koki Group
First written in FY2016. 5 of 6 entries say "Restated". Latest entry: FY2020.
0 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「Under our capital and business alliance with the Noritsu Koki Co.,Ltd. group, we are exploring new biotechnology business opportunities held by universities and public institutions in Japan and overseas, biotechnology ventures and companies. We are promoting the launch of new biotechnology businesses, including regenerative medicine, genetic diagnostics and gene therapy using these biotechnologies, with the aim of creating a long-term growth platform. We are actively exchanging information with the Noritsu Koki Co.,Ltd. group's drug discovery business division and exploring opportunities for collaboration.」
The company has reaffirmed its policy of exploring new biotechnology businesses and pursuing collaboration by leveraging the Noritsu Koki Co.,Ltd. group's network and capital and business alliance. - FY2019RestatedAnnual report
「Under our capital and business alliance with the Noritsu Koki Co.,Ltd. group, we are exploring new biotechnology business opportunities held by universities and public institutions in Japan and overseas, biotechnology ventures and companies. We are promoting the launch of new biotechnology businesses, including regenerative medicine, genetic diagnostics and gene therapy using these biotechnologies, with the aim of creating a long-term growth platform. We are actively exchanging information with the Noritsu Koki Co.,Ltd. group's drug discovery business division and exploring opportunities for collaboration.」
The company has reaffirmed its policy of exploring new biotechnology business opportunities and pursuing collaboration by leveraging the Noritsu Koki Co.,Ltd. group's network. - FY2018RestatedAnnual report
「Since June 2016, we have been part of a corporate group centered on our parent company, Noritsu Koki Co.,Ltd. Beginning with joint research and development with the group's drug discovery division, we are actively promoting joint research and development with external parties to commercialize promising healthcare opportunities held by universities and other research institutions, and have launched new biotechnology businesses, primarily in regenerative medicine, as future growth drivers.」
The company has reaffirmed its relationship with the Noritsu Koki Co.,Ltd. group, advancing joint research and development and new biotechnology businesses by leveraging the group's capital and network. - FY2017RestatedAnnual report
「Since June 2016, we have been part of a corporate group centered on our parent company, Noritsu Koki Co.,Ltd. As a member responsible for the group's healthcare business, we are accelerating research and development activities for biopharmaceuticals while also beginning to enter new biotechnology business areas by leveraging the group's network.」
The company has reaffirmed its relationship with the Noritsu Koki Co.,Ltd. group, leveraging its capital and network to accelerate research and development and enter new biotechnology businesses. - FY2017-Q1RestatedAnnual report
「Through a capital alliance, we secured stable development funding through a ¥2,000.001 million third-party allotment of new shares, with Launchpad12 GK as the subscriber, dated 13 April 2016, and a tender offer for our shares and other securities conducted from 15 April to 30 May 2016.」
The company continues to explain that it secured development funding through the third-party allotment and tender offer, as well as its collaboration with the Noritsu Koki Co.,Ltd. group. - FY2016First statedAnnual report
「Through a capital alliance, we secured stable development funding through a ¥2,000.001 million third-party allotment of new shares, with Launchpad12 GK as the subscriber, dated 13 April 2016, and a tender offer for our shares and other securities conducted from 15 April to 30 May 2016. Through a business alliance, we aim to further expand and commercialize our biotechnology business through mutual cooperation with biotechnology operating companies within the Noritsu Koki Co.,Ltd. group.」
Through the capital and business alliance, third-party allotment and tender offer, the company secured development funding and a basis for collaboration with the Noritsu Koki Co.,Ltd. group. As of the filing date, Launchpad12 and others had become the parent company.